{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Stage+Solid+Tumors&page=61",
    "query": {
      "condition": "Advanced Stage Solid Tumors",
      "page": 61
    },
    "page_size": 10
  },
  "pagination": {
    "page": 61,
    "page_size": 10,
    "total_count": 3086,
    "total_pages": 309,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Stage+Solid+Tumors&page=62&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Stage+Solid+Tumors&page=60&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T07:36:51.636Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00001428",
      "title": "A Phase II Study of 5-Fluorouracil Administered as a One Hour Infusion in Combination With Calcium Leucovorin and Interferon Alpha-2A in Advanced Colorectal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Neoplasms"
      ],
      "interventions": [
        {
          "name": "5-fluorouracil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 65,
      "start_date": "1995-02",
      "completion_date": "2000-12",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-11-19T07:36:51.636Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001428"
    },
    {
      "nct_id": "NCT05569057",
      "title": "A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Cutaneous T-cell Lymphoma (CTCL)"
      ],
      "interventions": [
        {
          "name": "SIM1811-03",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jiangsu Simcere Pharmaceutical Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2022-09-30",
      "completion_date": "2025-03-31",
      "has_results": false,
      "last_update_posted_date": "2022-10-07",
      "last_synced_at": "2026-11-19T07:36:51.636Z",
      "location_count": 6,
      "location_summary": "Detroit, Michigan • New York, New York • Huntersville, North Carolina + 2 more",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Huntersville",
          "state": "North Carolina"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05569057"
    },
    {
      "nct_id": "NCT04900519",
      "title": "Study of the Safety and Efficacy of STI-6643 in Subjects With Advanced Solid Tumors",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor",
        "Relapsed Solid Neoplasm",
        "Refractory Tumor"
      ],
      "interventions": [
        {
          "name": "STI-6643",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sorrento Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2021-11-24",
      "completion_date": "2025-03",
      "has_results": false,
      "last_update_posted_date": "2023-01-17",
      "last_synced_at": "2026-11-19T07:36:51.636Z",
      "location_count": 5,
      "location_summary": "San Diego, California • Sioux Falls, South Dakota • Austin, Texas + 2 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Sioux Falls",
          "state": "South Dakota"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04900519"
    },
    {
      "nct_id": "NCT07822919",
      "title": "A Study of AWT020 in Participants With Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Cancers (Solid Tumors)"
      ],
      "interventions": [
        {
          "name": "AWT020",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Anwita Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 96,
      "start_date": "2026-10-15",
      "completion_date": "2029-02",
      "has_results": false,
      "last_update_posted_date": "2026-11-17",
      "last_synced_at": "2026-11-19T07:36:51.636Z",
      "location_count": 3,
      "location_summary": "Plantation, Florida • Nashville, Tennessee • Fairfax, Virginia",
      "locations": [
        {
          "city": "Plantation",
          "state": "Florida"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07822919"
    },
    {
      "nct_id": "NCT05382325",
      "title": "A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced or Metastatic Solid Tumors"
      ],
      "interventions": [
        {
          "name": "MK-1484",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2022-06-16",
      "completion_date": "2026-09-29",
      "has_results": false,
      "last_update_posted_date": "2026-10-21",
      "last_synced_at": "2026-11-19T07:36:51.636Z",
      "location_count": 2,
      "location_summary": "Sioux Falls, South Dakota • San Antonio, Texas",
      "locations": [
        {
          "city": "Sioux Falls",
          "state": "South Dakota"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05382325"
    },
    {
      "nct_id": "NCT02526017",
      "title": "Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Head and Neck Cancer",
        "Pancreatic Cancer",
        "Ovarian Cancer",
        "Renal Cell Carcinoma",
        "Malignant Glioma",
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Cabiralizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Five Prime Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 313,
      "start_date": "2015-09-08",
      "completion_date": "2019-11-18",
      "has_results": true,
      "last_update_posted_date": "2022-03-09",
      "last_synced_at": "2026-11-19T07:36:51.636Z",
      "location_count": 39,
      "location_summary": "Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 27 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02526017"
    },
    {
      "nct_id": "NCT05150691",
      "title": "A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HER2-positive Advanced Solid Tumor"
      ],
      "interventions": [
        {
          "name": "DB-1303/BNT323",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pertuzumab Injection",
          "type": "DRUG"
        },
        {
          "name": "Ritonavir",
          "type": "DRUG"
        },
        {
          "name": "Itraconazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "DualityBio Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 796,
      "start_date": "2022-01-31",
      "completion_date": "2027-10",
      "has_results": false,
      "last_update_posted_date": "2026-08-27",
      "last_synced_at": "2026-11-19T07:36:51.636Z",
      "location_count": 35,
      "location_summary": "Cerritos, California • Los Angeles, California • San Diego, California + 29 more",
      "locations": [
        {
          "city": "Cerritos",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Coral Springs",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05150691"
    },
    {
      "nct_id": "NCT00520390",
      "title": "A Phase I, Study to Evaluate the Safety and Tolerability of Intravenous EZN-2208 in Patients With Advanced Solid Tumors or Lymphoma (EZN-2208-02)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma",
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "EZN-2208",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Enzon Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2007-05",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2010-04-02",
      "last_synced_at": "2026-11-19T07:36:51.636Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00520390"
    },
    {
      "nct_id": "NCT05375084",
      "title": "SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer",
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "BBP-398 with nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Navire Pharma Inc., a BridgeBio company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2022-10-20",
      "completion_date": "2024-07-15",
      "has_results": false,
      "last_update_posted_date": "2024-12-12",
      "last_synced_at": "2026-11-19T07:36:51.636Z",
      "location_count": 15,
      "location_summary": "Springdale, Arkansas • La Jolla, California • Santa Rosa, California + 11 more",
      "locations": [
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05375084"
    },
    {
      "nct_id": "NCT04147247",
      "title": "A Trial to Find the Safe Dose for BI 905681 in Patients With Incurable Tumours or Tumours That Have Spread",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "BI 905681",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2019-12-23",
      "completion_date": "2021-05-27",
      "has_results": true,
      "last_update_posted_date": "2023-11-29",
      "last_synced_at": "2026-11-19T07:36:51.636Z",
      "location_count": 3,
      "location_summary": "Sarasota, Florida • Philadelphia, Pennsylvania • Nashville, Tennessee",
      "locations": [
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04147247"
    }
  ]
}